PNC Financial Services Group
ARTL icon

PNC Financial Services Group’s Artelo Biosciences ARTL Stock Holding History

PNC Financial Services Group’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$104 – 4622
2023
Q3 		$104 Buy
+4
New +$133 ﹤0.01% 4563

Other funds holding ARTL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

PNC Financial Services Group's ARTL Position: Q4 2023 in Review

PNC Financial Services Group sold out of Artelo Biosciences (ARTL) in Q4 2023, closing a stake of 4 shares — an estimated $104 sold.

PNC Financial Services Group first reported a position in ARTL in Q3 2023 and held it in 1 quarter. The position peaked at $104 in Q3 2023. 4 funds tracked by Wall St. Rank hold ARTL as of Q4 2023.

  • PNC Financial Services Group reported no remaining Artelo Biosciences position as of Q4 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 4 Artelo Biosciences shares in Q4 2023, an estimated $104.
  • PNC Financial Services Group first reported a position in Artelo Biosciences in Q3 2023 and held it in 1 quarter.
  • PNC Financial Services Group's Artelo Biosciences position peaked at $104 in Q3 2023.
  • 4 funds tracked by Wall St. Rank held Artelo Biosciences as of Q4 2023.

Based on PNC Financial Services Group's 13F filing for Q4 2023, filed 9 Feb 2024.